Market Overview

UPDATE: Gilford Securities Initiates Speculative Buy on Echo Therapeutics


Gilford Securities initiates its coverage on Echo Therapeutics (NASDAQ: ECTE) with a Speculative Buy on the company;s potential of becoming a world leader in transdermal drug delivery and analyte monitoring.

Gilford Securities says, "The overall Transdermal market is thought to range somewhere up to $20 billion now. However, its long-term potential seems open-ended. In the drug delivery area alone, for example, today's market is comprised of approximately 20 drugs. The potential is easily hundreds. Within this possibly disruptive transformational technology, Echo seems to enjoy a world leading technology and a capable management team with which to exploit long-term possibilities."

ECTE closed at $1.84 a share yesterday.

Posted-In: gilford securitiesAnalyst Color Price Target Initiation Intraday Update Analyst Ratings


Related Articles (ECTE)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→